Bertis’ 'MASTOCHECK®' Promotes the Importance of Regular Breast Cancer Screening at the 2025 Pink Run

- Participated as a sponsor in the October Breast Cancer Awareness Month event 

- Operated the MASTOCHECK® promotional booth highlighting the need for regular breast cancer screening

On October 13, Bertis, a company specializing in proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it participated in the 2025 Pink Run held on October 12 at Peace Plaza in Sangam World Cup Park, introducing its breast cancer early-detection blood test, MASTOCHECK®, and promoting the importance of regular breast cancer screening. 

The Pink Run, part of the Pink Ribbon Campaign, is jointly hosted by the Korea Breast Cancer Foundation, the Korean Breast Cancer Society, the Korean Cancer Association, and the Seoul Foundation of Women & Family. The event aims to raise public awareness of breast health and encourage women to practice regular breast cancer screening. Celebrating its 25th anniversary this year, the event gathered about 5,000 pre-registered participants who shared their commitment to breast health. Participants took part in 5 km and 10 km runs, as well as various on-site programs and events designed to highlight the importance of early detection and regular screening for breast cancer. 

In celebration of Breast Cancer Awareness Month, Bertis joined the event as a sponsor and operated a promotional booth at the venue. The booth featured MASTOCHECK® and provided information on the importance of regular breast cancer screening and testing methods through quiz events, drawing strong interest and engagement from participants. 

MASTOCHECK® is the world’s first commercialized proteomics-based blood test for early breast cancer detection, developed by Bertis. Having been approved by the Ministry of Food and Drug Safety (MFDS) for its validated effectiveness in detecting early-stage (Stage 0–2) breast cancer, MASTOCHECK® offers a convenient, non-invasive blood test option free from radiation exposure or discomfort. It also allows screening for women in their 20s and 30s who are not typically recommended for mammography. The test is currently available at more than 550 hospitals and health screening centers across Korea. 

Seung-man Han, CEO of Bertis, said, "Following our participation in last year’s Pink Ribbon campaign, we are honored to take part in this year’s Pink Run to help raise public awareness of breast health and the importance of regular screening. Bertis will continue to contribute to the early detection and awareness of major diseases, including breast cancer, through innovative early-diagnosis solutions such as MASTOCHECK®.”